NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Significant Decline in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 258,100 shares, a decline of 32.6% from the October 31st total of 383,000 shares. Based on an average daily volume of 237,200 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.8% of the company’s stock are short sold.

NeuroSense Therapeutics Stock Up 2.7 %

NASDAQ:NRSN traded up $0.03 during trading hours on Friday, reaching $0.96. 294,809 shares of the company traded hands, compared to its average volume of 255,939. The business’s 50-day moving average price is $1.19 and its two-hundred day moving average price is $1.05. NeuroSense Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd bought a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned 0.24% of NeuroSense Therapeutics as of its most recent filing with the SEC. 1.04% of the stock is currently owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.